dolutegravir/rilpivirine (Juluca)

Indications

• treatment of HIV1

* viral suppression on a stable regimen for 6 months or more

* no history of treatment failure

Dosage

PO QD

Adverse effects

• diarrhea
• headache
• skin rash
• allergic reactions
• hepatotoxicity
• depression or mood changes

Drug interactions

• should not be given with other HIV1 antiretroviral agents

More general terms

• antiretroviral combination

Components

• dolutegravir (Tivicay, DTG)
• rilpivirine (Edurant, RPV)